



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 74853

**Title:** Short term safety of coronavirus disease 2019 (COVID-19) vaccines in patients with solid tumors receiving systemic therapy

**Provenance and peer review:** Invited manuscript; externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06245769

**Position:** Peer Reviewer

**Academic degree:** MSc

**Professional title:** Lecturer

**Reviewer's Country/Territory:** Ethiopia

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-16 02:49

**Reviewer performed review:** 2022-01-17 20:35

**Review time:** 1 Day and 17 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input type="checkbox"/> ] Anonymous [ <input checked="" type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

1. The findings of the study descriptive analysis shows that COVID-19 vaccine are safe for cancer patients. 2. The manuscript is fair in quality. Basic methodological procedures were not followed or described in the text. It is not possible to provide further comments for such study limited to descriptive statistics only. 3. The study has many limitations from writing standard to poor methodological explanations. There is also duplication of data presentation. See attached document!!



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 74853

**Title:** Short term safety of coronavirus disease 2019 (COVID-19) vaccines in patients with solid tumors receiving systemic therapy

**Provenance and peer review:** Invited manuscript; externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05631502

**Position:** Peer Reviewer

**Academic degree:** BSc, MBBS, MD

**Professional title:** Academic Fellow, Academic Research, Doctor

**Reviewer's Country/Territory:** Qatar

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-18 07:09

**Reviewer performed review:** 2022-01-18 14:13

**Review time:** 7 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
---------------------------------	---

### SPECIFIC COMMENTS TO AUTHORS

I would like to thank the authors to have conducted this important study and this exercise is generally of benefit. However, I have some comments that should be addressed before processing the article further.

- Generally, to assess the safety profile of vaccines we need a longitudinal study design following patients for years. Given the current pandemic it is natural that evidence needs to be floated and provided to the readership. To tackle this, I would highly suggest the authors to change the title to short term safety rather than just safety which is very broad.
- There are multiple studies on solid cancer patients concerning COVID vaccine which the authors failed to cite, acknowledge and discuss. I can place some examples here: 1. Kian W, Zemel M, Kestenbaum EH, Rouvinov K, Alguayn W, Levitas D, Ievko A, Michlin R, Abod MA, Massalha I, Chernomordikov E, Sharb AA, Shalata W, Levison E, Roisman LC, Lavrenkov K, Peled N, Neshet L, Yakobson A. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study. *Medicine (Baltimore)*. 2022 Jan 14;101(2):e28561. doi: 10.1097/MD.00000000000028561. PMID: 35029223. 2. Lasagna A, Lilleri D, Agustoni F, Percivalle E, Borgetto S, Alessio N, Comolli G, Sarasini A, Bergami F, Sammartino JC, Ferrari A, Zavaglio F, Arena F, Secondino S, Falzoni M, Schiavo R, Lo Cascio G, Cavanna L, Baldanti F, Pedrazzoli P, Cassaniti I. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up. *ESMO Open*. 2021 Dec 11;7(1):100359. doi: 10.1016/j.esmoop.2021.100359. Epub ahead of print. PMID: 34973510; PMCID:



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

PMC8664661. 3. Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, Chikamori K, Kudo K, Ochi N, Harada D, Maeda Y, Kiura K. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study. *Thorac Cancer*. 2021 Dec 28. doi: 10.1111/1759-7714.14281. Epub ahead of print. PMID: 34964270. • English language is up to the mark and does not require any editing.



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 74853

**Title:** Short term safety of coronavirus disease 2019 (COVID-19) vaccines in patients with solid tumors receiving systemic therapy

**Provenance and peer review:** Invited manuscript; externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05738088

**Position:** Editorial Board

**Academic degree:** MSc, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-11

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-01-18 14:02

**Reviewer performed review:** 2022-01-19 12:41

**Review time:** 22 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

### **SPECIFIC COMMENTS TO AUTHORS**

The author evaluates the safety of COVID-19 vaccines in patients with solid tumors undergoing systemic therapies. However, the paper needs further improvements. Suggestions to improve : 1. Kindly highlight the novelty of the proposed method in detail. 2. Discuss more detail about results and experiments. 3. Electronic medical records were accessed to collect information on patient characteristics, systemic therapies, type of vaccine received, and adverse effects associated with the vaccine administration. How records were accessed? 4. Please compare your proposed method with existing methods and show the differences in a table. Our study showed that the administration of COVID-19 vaccines in solid tumor patients receiving systemic therapy is safe and should be encouraged. 5. Figures, diagrams are not sufficient (0 ), please add some figures and diagrams. Which increases the quality of the manuscript. 6. Please check the format of text and tables, Proofreading the entire manuscript once. Please refer and cite. DOI: 10.1016/j.ipm.2021.102810 DOI: 10.1016/j.chaos.2021.110708 DOI: 10.1016/j.rinp.2021.103813



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Clinical Oncology*

**Manuscript NO:** 74853

**Title:** Short term safety of coronavirus disease 2019 (COVID-19) vaccines in patients with solid tumors receiving systemic therapy

**Provenance and peer review:** Invited manuscript; externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06245769

**Position:** Peer Reviewer

**Academic degree:** MSc

**Professional title:** Lecturer

**Reviewer's Country/Territory:** Ethiopia

**Author's Country/Territory:** United States

**Manuscript submission date:** 2022-01-11

**Reviewer chosen by:** Ji-Hong Liu

**Reviewer accepted review:** 2022-04-13 07:15

**Reviewer performed review:** 2022-04-14 06:59

**Review time:** 23 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous





**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**https://**[www.wjgnet.com](https://www.wjgnet.com)

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

Comments were addressed.